Alpha Tau Medical (DRTS)
Develops Alpha DaRT, a localized alpha-radiation therapy for solid tumors.
Something off on this page? Send us feedback.
Develops Alpha DaRT, a local alpha-radiation platform for solid tumors. The clinical-stage business depends on advancing that single technology through trials, regulation, and commercialization.
Alpha DaRT is a local alpha-radiation platform designed for solid tumors. Operations span technology and IP development, pre-clinical and clinical research, and preparation for commercialization. The core facility is in Jerusalem and most of the workforce is in Israel, while subsidiaries establish an operating presence in the United States, Japan, and Canada.
In Japan, Alpha DaRT has marketing approval for unresectable locally advanced or locally recurrent head-and-neck cancer. In the United States, the platform remains in development toward possible FDA approval; at the reporting date, no product had been approved for sale there. The business depends on clinical-trial enrollment, regulatory compliance, intellectual-property protection, and access to capital.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 3, 2026 | Barclays | Reiterate | Rating: —Target: $17 | Target: $30 |
| Aug 11, 2026 | H.C. Wainwright | Target | Target: $15 | Target: $16 |
| Jun 4, 2026 | Barclays | Reiterate | Rating: —Target: $15 | Target: $17 |
| May 28, 2026 | Barclays | Target | Target: — | Target: $15 |
| May 19, 2026 | Piper Sandler | Reiterate | Rating: —Target: $7 | Target: $8 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $100.6M · Total debt $15.2M · Total assets $134.3M · Shareholders' equity $44.1M
- Revenue
- $0
- Operating income
- −$13.8M
- Net income
- −$45.8M
No dividends on record.
| Institutions | 9.04% | 7.95M ADS | |
|---|---|---|---|
| 80 holders · as of Jun 30, 2026 | |||
| Insiders | 17.87% | 15.73M ADS | |
| 9 holders · as of Aug 25, 2026 | |||
| Other | 73.09% | 64.33M ADS | |
| remainder | |||
88.01M ADS as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Uzi Sofer1,2Insiderdirector, officer: Chief Executive Officer | 15.57% | 13.70M ordinary | filed Jun 30, 2025 |
Michael AvruchInsiderdirector | 1.79% | 1.57M ordinary | filed Mar 18, 2026 |
Gem Investment Advisors, LLCInstitution | 1.63% | 1.43M ADS | as of Jun 30, 2026 |
Hightower Advisors, LLCInstitution | 0.99% | 874,994 ADS | as of Jun 30, 2026 |
Boothbay Fund Management, LLCInstitution | 0.88% | 773,481 ADS | as of Jun 30, 2026 |
- Uzi Sofer's transaction reports restate only vehicles that traded; the 2025 ownership statement (13.70M) is used instead.
- Uzi Sofer reports a block also reported by Michael Avruch; it is counted once, under Michael Avruch.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 21, 2026 | Raphi Levy | officer: Chief Financial Officer | −2,871 | $15.00 |
| Aug 11, 2026 | Raphi Levy | officer: Chief Financial Officer | −17,730 | $14.00 |
| Jul 6, 2026 | Raphi Levy | officer: Chief Financial Officer | −2,270 | $14.00 |
| Jul 2, 2026 | Raphi Levy | officer: Chief Financial Officer | −17,873 | $13.00 |
| Jul 1, 2026 | Raphi Levy | officer: Chief Financial Officer | −2,127 | $13.02 |
- Accuray
Robotic radiosurgery and IMRT systems for cancer treatment
- Nanobiotix (ADR)
Intratumoral radioenhancement activated by radiation therapy
- Boston Scientific
Y-90 radioembolization for hepatocellular carcinoma
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Alpha Tau Medical | $15.29 | −1.35% | $1.40B | — | — | — | — |
| Accuray | $0.2385 | −0.63% | $28.6M | — | — | 0.1 | −20.9% |
| Nanobiotix (ADR) | $34.58 | +0.22% | $1.75B | — | — | 51.4 | — |
| Boston Scientific | $44.61 | +2.04% | $64.98B | 17.8 | 13.6 | 3.1 | +7.5% |
| Median | 17.8 | 13.6 | 3.1 | −6.7% |